Subcutaneous Elafin in Healthy Subjects

Subcutaneous Elafin in Healthy Subjects

A multiple-ascending-dose (MAD), randomized, placebo-controlled, blinded trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of Elafin in healthy adult subjects. The purpose of this study is to assess Elafin that is being developed for treatment of PAH. Elafin inhibits elastase, an enzyme that is increased in pulmonary hypertension and is a major factor in the development of PAH. Elafin will be administered subcutaneously daily for 7 days in normal healthy subjects followed over a 28 day time period.

Pharmaceutical medication involved
Patients and healthy individuals accepted

Drug - Elafin

Elafin subcutaneous.

Drug - Placebo

Placebo subcutaneous.

Safety and Tolerability of Escalating Doses of Subcutaneous Elafin (Tiprelestat) Injection in Healthy Normal Subjects